Please assess the completion status of the following clinical trial:

Trial Title: Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Newly-diagnosed with mantle cell lymphoma (MCL) with accessible disease site for excisional biopsy, OR have sufficient peripheral blood tumor to leukapherese ≥ 1.5 x 10e9 lymphoma cells in a single session~* Medically appropriate by standard clinical criteria to receive rituximab and standard induction chemotherapy and high-dose chemotherapy with autologous hematopoietic cell transplant (AHCT)~* HIV-negative~* Eastern Cooperative Oncology Group (ECOG) Performance Status, OR Karnofsky performance scale 50 to 100%~* Capable of providing informed consent~EXCLUSION CRITERIA~* Currently receiving immunosuppressive medications~* Severe psychological or medical illness~* Pregnant or lactating~* Unable to safely complete the study, at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CpG-MCL Vaccine (Type: EXPERIMENTAL): An autologous anti-tumor vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).